



International workshops on interim PET in lymphoma

History and Perspective

Aaron Polliack, Jerusalem, Israel

Michel Meignan, Créteil, France



**First international workshop on interim PET
In Lymphoma**
April 3-4, 2009,
Deauville, France
(M Meignan, A Gallamini, C Haioun)



14^e JOURNEES DU GELA
Centre International de Deauville
1 avenue Lucien Barrière
14800 Deauville
Deauville 2-3-4 avril 2009

54 registered




Five-point scale/Deauville criteria

1. no uptake
2. uptake \leq mediastinum
3. uptake $>$ mediastinum but \leq liver
4. uptake $>$ liver at any site
5. uptake \gg liver and/or new sites of disease

1 Investigate SUV and Δ SUV

2 Launch IVS in HL and NHL



Nuclear medicine and Hematologists are moving forward together!!!

Leukemia & Lymphoma, August 2009; 50(8): 1257–1260

Report on the First International Workshop on interim-PET scan in lymphoma

MICHEL MEIGNAN¹, ANDREA GALLAMINI², & CORINNE HAIOUN³

¹Nuclear Medicine Department, H. Mondor Hospital, AP-HP/Paris 12 University, Creteil, France, ²Hematology Department and BMT Unit, Az. Ospedaliera S. Croce e Carle, Cuneo, Italy, and ³Hematology Department, H. Mondor Hospital, AP-HP/Paris 12 University, Creteil, France


(Received 8 May 2009; accepted 12 May 2009)



**Second international workshop on
interim PET
in Lymphoma**
April 8-9, 2010,
Menton, France
(M Meignan, A Gallamini, C Haioun)



143 registered



Leukemia & Lymphoma, December 2010; 51(12):2171-80

Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8–9 April 2010

MICHEL MEIGNAN¹, ANDREA GALLAMINI², CORINNE HAIOUN¹, & AARON POLLIACK³


¹*Nuclear Medicine Department and Lymphoma Unit, Hôpital Henri Mondor, Créteil, France,* ²*Hematology Department and BMT Unit, Az. Ospedaliera S. Croce e Carle, Cuneo, Italy,* and ³*Department of Hematology, Hadassah University Hospital and Hebrew University Medical School, Jerusalem, Israel*

(Received 23 September 2010; accepted 26 September 2010)

**Third international workshop on interim
PET
in Lymphoma**
September 25-27, 2011
Menton, France



Interim PET is still moving
178 registered, 23 countries

Adresse  <http://clinicaltrials.gov/ct2/results?term=PET+lymphoma>

ClinicalTrials.gov

A service of the U.S. National Institutes of Health

List Results

[Refine Search](#)

[Results by Topic](#)

[Results on Map](#)

[Search Details](#)

Found 145 studies with search of: PET lymphoma

45 trials ongoing worldwide
based-on or evaluating interim
PET

PET- where do we stand now ?

- Plays a central role in management of pts with HD , and DLBCL - staging and at end of therapy BUT is it reliable enough for predicting outcome at mid-term (?)
- Issues relating to PPV / tailoring of therapy still ongoing
- Probably improves outcome due to better staging and probably also morbidity due to possible positive effects of “tailoring “ of therapy ?
- PET status prior to SCT predicts outcome established

PET – can we agree perhaps ?

- Reliable for HD ,DLBCL and grade III subtypes of FL
- Replace BMB in early stage HD and DLBCL ? for FOCAL involvement when present (diffuse pattern is regarded as “reactive “
- Less obvious for DLBCL – better for concordant lymphoma than discordant as small cells are not avid
- FL has low sensitivity – so not to be done ? What about - Grade III FL ? - New tracers needed?

Problems and some questions?

- PMBCL - Similar to DLBCL ? Interim PET
- MCL- unreliable – early and late ?
- T-NHL – very unreliable – why ?
- Non FL small cell LY/ CLL – no PET at all ?
 - but grade by PET for transformation - when to do ?
- EXTRANODAL LY – unreliable ?
- Bone involvement LY ? accuracy ?

Future issues – agreement ?

- Can PET-CT replace CT “formally “ in staging guidelines for HL and some NHL ?
- Are we indeed closer to recommending it in practice for therapy adjustments/tailoring? In which LY ? and when ?
- Can we firmly recommend a schedule for **surveillance after CR** for different lymphomas ?

Future issues

- New tracers for low sensitivity LY ?
- ^{18}F deoxy-fluorothymidine for tumor proliferative activity and BM regeneration
- Fluoro-ethyl tyrosine (FET) –amino acid analogue is highly specific
- Radiolabelled peptides and mo abs
- Resurge of Gallium*68
- Novel imaging for bulk and volume

Further Perspectives

- Increased development of various PET applications in lymphoma, new radiotracers and new imaging modalities
- Evolving drugs: the era of targeted therapy could change the way we use PET

Some future questions for the audience:

- Focus the next meetings only on interim PET?
- Extend to all indications of PET in lymphoma ± other imaging modalities in lymphoma ?
- World group or society on functional imaging in lymphoma?
- **THANK YOU for attention !**